Bavarian's Mpox Vaccine Targets Infectious Disease in Toddlers
Tuesday, 29 October 2024, 07:09
Infectious diseases present serious risks to young children, which is why Bavarian has initiated a Phase II trial for its mpox/smallpox vaccine aimed at children between 2 and 11 years old. This registrational trial is crucial as it seeks to support the vaccine's approval for pediatric use, enhancing our public health arsenal against infectious diseases.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.